An Overview of the NeoMONARCH Trial in HR+/HER2- Breast Cancer

For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

With the clearance of an investigational new drug application for BTX-9341 from the FDA, a phase 1 trial will evaluate the agent in HR-positive/HER2-negative breast cancer.

In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.